Aardvark Therapeutics (AARD) Payables (2024 - 2026)
Aardvark Therapeutics (AARD) posted Payables of $4.5 million for Q1 2026, up 116.84% sequentially from $2.1 million in Q4 2025, and up 75.78% YoY from $2.6 million in Q1 2025.
Aardvark Therapeutics (AARD) Payables (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Payables for 3 years, with the latest figure at $4.5 million in Q1 2026.
- Quarterly Payables rose 75.78% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (up 75.78% YoY) and the FY2025 annual result came in at $2.1 million, down 9.83% from the prior year.
- Payables improved to $4.5 million in Q1 2026 per AARD's latest filing, from $2.1 million in the prior quarter.
- Over five years, Payables peaked at $5.1 million in Q2 2025 and troughed at $2.1 million in Q4 2025.
- A 3-year average of $3.5 million and a median of $3.5 million in 2025 frame the typical range for Payables.
- The sharpest annual moves came in 2025 and 2026: Payables fell 9.83% in 2025, then jumped 75.78% in 2026.
- Over 3 years, Payables stood at $2.3 million in 2024, then retreated by 9.83% to $2.1 million in 2025, then surged by 116.84% to $4.5 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $4.5 million, $2.1 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Aardvark Therapeutics | 127.36 Mn | 53.44 Mn | - | 2.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.09 Mn |
| Mar 31, 2026 | 4.49 Mn |
| Dec 31, 2025 | 2.07 Mn |
| Sep 30, 2025 | 4.44 Mn |
| Jun 30, 2025 | 5.06 Mn |
| Mar 31, 2025 | 2.56 Mn |
| Dec 31, 2024 | 2.30 Mn |